Department of Bioengineering, College of Engineering, Hanyang University, 222 Wangsimni-ro, Seongdong-gu, 133- 791, Seoul, Korea.
Curr Cancer Drug Targets. 2018;18(2):139-152. doi: 10.2174/1568009617666170222123406.
Novel treatment modalities are rapidly advancing toward clinical use as many malignant cancers still remain incurable. Adenovirus (Ad) in particular has been extensively researched as a promising alternative to conventional cancer therapy in the past decades. Although Ad has demonstrated promising therapeutic outcome and cancer specificity in preclinical models, its therapeutic efficacy in clinical trials is still insufficient due to several drawbacks such as rapid clearance of viral particles by host immune response, induction of acute inflammatory response, and hepatotoxicity. In this regard, combination of Ad with other cancer treatment modalities, such as chemotherapy, radiotherapy, or immunotherapy, can be an effective strategy to overcome the limitations of Ad. Cancerspecific and effective expression of multifunctional therapeutic genes by Ad can enhance the therapeutic profile of other treatment modalities, making it a logical candidate for combination therapy to combat malignant tumors.
新型治疗方法正在迅速推进到临床应用，因为许多恶性癌症仍然无法治愈。在过去的几十年里，腺病毒（Ad）作为传统癌症治疗的一种有前途的替代方法，已经得到了广泛的研究。尽管 Ad 在临床前模型中显示出了有希望的治疗效果和癌症特异性，但由于宿主免疫反应迅速清除病毒颗粒、诱导急性炎症反应和肝毒性等几个缺点，其在临床试验中的疗效仍然不足。在这方面，将 Ad 与其他癌症治疗方法（如化疗、放疗或免疫疗法）相结合，可以是克服 Ad 局限性的有效策略。Ad 对多功能治疗基因的特异性和有效表达可以增强其他治疗方法的治疗效果，使其成为联合治疗恶性肿瘤的合理候选药物。
